ArticleJournal of experimental & clinical cancer research : CR2022

Clinically relevant CHK1 inhibitors abrogate wild-type and Y537S mutant ERα expression and proliferation in luminal primary and metastatic breast cancer cells.

Sara Pescatori et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.